As we begin another American Society of Clinical Oncology (ASCO) annual meeting (June 2-6, Chicago, Illinois), Janssen Oncology is excited to be presenting a wealth of data across prostate and blood cancers. In total, 19 company-sponsored abstracts have been accepted for presentation, including new data for both investigational and approved oncology compounds. This is the second year that our data will be featured in the ASCO Plenary session, which highlights studies deemed to have the highest scientific merit and greatest potential impact on patient care.

“We are focused on delivering therapies that not only treat cancer, but aim to intercept and eliminate disease,” said Peter F. Lebowitz, M.D., Ph.D., Oncology Therapeutic Area Head, Janssen Research & Development. “We continue to investigate ways in which our medicines can potentially benefit patients at earlier stages of their disease, and we are excited to share emerging data at ASCO for our therapies.”

Cancer remains the second leading cause of premature death in Europe(1), and Janssen is striving to address the ongoing unmet needs by pursuing the cancer types and sub-types we know best and where we can achieve the highest impact. The wealth of data that is being shared at ASCO demonstrates our commitment to discovering first of a kind, innovative medicines for cancers where there are limited treatment options.

back to Janssen EMEA stories